Entered into the annals of history.
Author / ASI Revelation
Source / New Intelligence
(ID: AI_era)
For the first time in history, humans have helped cure cancer with the aid of AI! The global medical community is greeted with a seismic event that will be remembered in history.
The global mRNA giant Moderna and Merck jointly announced—
They have developed the first personalized mRNA cancer therapy intismeran autogene, achieving historic success in a global Phase III clinical trial targeting high-risk melanoma.
Both key endpoints of "recurrence-free survival" and "distant metastasis-free survival" have been achieved!
As soon as the news broke, Wall Street erupted.
Moderna's stock price surged over 100% to 170% in a single day, with its market value soaring by billions of dollars.
Merck also surged, and the Nasdaq biotechnology index hit a historic high!
However, what is even more commendable is the revolutionary significance behind the technology.
This is the first time in human history that AI has been deeply involved in target design and customized an exclusive mRNA anti-cancer drug based on genetic mutations of cancer cells in patients!
Elon Musk stated: Artificial RNA essentially turned healing into a software problem.
Karen Knudsen, CEO of the American Parker Institute for Cancer Immunotherapy, expressed:
This significant victory marks the official entry of solid tumor treatments into a new era of immunotherapy. This is an extremely bright start, and the curtain of a new era has been raised!
In 2020, mRNA technology completed the journey from viral sequence to vaccine approval in just 11 months, helping humanity withstand a pandemic; by 2026, the same platform, aided by AI, has decisively repelled cancer in a Phase III trial for the first time.
"Black Death": A century-long nightmare in humanity's fight against cancer
To understand how monumental this breakthrough is, we must first recognize the ferocity of the opponent.
This clinical trial focused on melanoma. Although it accounts for only about 1% of all skin cancers, it is highly malignant and one of the leading causes of death from skin cancer.
Melanoma is considered one of the "kings of cancer," and the reasons are extremely brutal.
It often arises from a seemingly inconspicuous black mole; if not careful, it can rapidly spread to core organs like the lungs, liver, and brain through lymph and blood.
Moreover, it has a very high recurrence rate; even after surgically removing the tumor, hidden residual cancer cells can resurface within 2 to 3 years.
For many years, the most effective treatment has been Merck's "king of drugs"—Keytruda (K drug, PD-1 inhibitor).
The principle of K drug is to "release the immune brake" in the human body, allowing T cells to attack cancer cells.
However, it has a fatal shortcoming: if the patient's immune system cannot "recognize" what dormant cancer cells look like, even if the brake is released, the immune army will just be aimlessly wandering within the body.
Post-surgical recurrence, distant metastasis, drug resistance... Millions of patients still undergo torment.
This time, humanity has finally awaited a "searchlight" capable of illuminating the disguise of cancer cells in the dark.
AI personally issues “exclusive wanted orders” to the immune system
Moderna and Merck have pioneered a true "one person, one drug" era.
And the core of this treatment process is the AI algorithm.
This revolutionary surgical-level precision therapy can identify mutations and find the "fingerprints" of cancer cells.
Doctors excise tumor tissue from patients and draw a sample of healthy blood for comprehensive high-throughput gene sequencing. By comparing the DNA of healthy cells and cancer cells, unique gene mutations of the patient's tumor can be identified.
The next step is AI intervention, which pinpoints the most lethal "34 targets" from tens of thousands of mutations.
Each patient may have thousands of mutations; which few mutations can maximally activate the immune system?
Relying solely on human scientists to experimentally screen them would take years or even decades, and patients cannot wait.
At this point, the AI model comes into play.
The AI algorithms deeply integrated by Moderna rapidly simulate protein folding, binding power predictions, and immune responses within hours, ultimately selecting up to 34 "new antigens" with the highest immune killing power from a vast array of mutations.
Rapid customization: One exclusive mRNA for each person
Moderna's super-automated platform quickly writes and synthesizes a string of mRNA sequences exclusive to the patient based on the 34 targeted points selected by AI, encasing them in lipid nanoparticle (LNP).
When this unique vaccine is injected into the patient's body, it directs healthy cells to express the 34 mutation protein fragments that only exist on cancer cells.
This is tantamount to delivering a "3D high-definition wanted order" of the dormant cancer cells within this patient directly into the hands of immune T cells!
At this moment, when combined with K drug to release the immune brake, the already well-trained and armed T cell army will launch a comprehensive search in every corner of the body, accurately hunting down and completely eliminating any lingering hidden cancer cells!
Without harming innocent normal cells, it solely targets cancer cells bearing specific mutations—this is the precise medicine humanity has long desired!
After administration, the mRNA-encoded new antigen sequence is translated in the body and presented to the immune system, which is a critical step in generating an immune T cell response against cancer cells. The mRNA sequence is transient and will not integrate into DNA.
Crossing the "valley of death":
The first mRNA cancer therapy to achieve Phase III success
In the drug development field, there is an accepted law: "Phase II brings hope, Phase III buries everything."
Countless cancer drugs and vaccines that were once highly anticipated eventually fell in large-scale, rigorously standardized randomized double-blind Phase III clinical trials.
But this time, Moderna and Merck created a miracle!
This was a global Phase III clinical trial involving 1,137 high-risk melanoma patients who had already undergone surgical excision of lesions.
The trial adopted the highest standards of randomization, double-blinding, and placebo control:
One group received: personalized mRNA vaccine + K drug combination therapy;
Another group received: standard therapy (K drug alone) for about a year.
The midterm analysis results thoroughly shocked the clinical medical community.
Firstly, the primary endpoint achieved overwhelming success.
The mRNA vaccine group showed statistically significant and clinically meaningful prolongation in recurrence-free survival (RFS)!
Secondly, all secondary endpoints were met: significantly reduced the risk of tumor metastasis to distant body regions (such as lungs, brain, liver) (DMFS met)!
Additionally, it demonstrated excellent safety.
Both companies confirmed no new unexpected safety signals in the combination therapy; side effects were generally similar to those of regular vaccines, with good tolerance.
It is noteworthy that in previously published long-term follow-up data from Phase IIb, this combination therapy reduced the risk of recurrence or death by 49% over a period of five years, with the risk of distant metastasis or death dropping by 59%!
Professor Lennard Lee, a top cancer expert at Oxford University, excitedly commented:
This is the world’s first individualized new antigen therapy to achieve positive results in a Phase III clinical trial and the first successful mRNA cancer treatment program. In just a few short years since the COVID pandemic, we have already welcomed an mRNA vaccine capable of treating cancer, marking an epoch-making milestone!
When AI finally begins to save lives
Moderna and Merck have given the world the loudest and most powerful answer—
The true destination of AI has never been to compete for jobs at the bottom level or to serve as digital toys for chatting, but to stand at the forefront of human intelligence to solve the debilitating diseases that have plagued humanity for centuries!
In the past, there was a famous "10-10 rule" in new drug development—taking 10 years, costing 1 billion dollars, and succeeding less than 10% of the time.
However, in the field of personalized cancer treatment, because everyone's mutations vary greatly, without AI's massive computational power and target prediction capability, "one person, one drug" is an absolute impossibility in terms of economics and time costs.
The "AI + mRNA customized vaccine" therapy may signify that the day when humanity overcomes cancer is truly coming.
AI is bringing the dream of curing all diseases closer!
Which cancers will embrace dawn?
More significantly, this breakthrough is certainly not limited to just melanoma.
As noted by Moderna's CEO Stéphane Bancel and Merck's research laboratories president Dean Li, melanoma is merely a "testing stone" for this AI + mRNA platform.
As long as this underlying logic (tumor sequencing ➡️ AI selects new antigens ➡️ customized mRNA ➡️ activates immunity) is proven in Phase III trials, this technology can theoretically be replicated for all solid tumors with genetic mutations!
Currently, Moderna and Merck have launched multiple global clinical trials to push this AI customized vaccine towards more significant cancers, such as non-small cell lung cancer, pancreatic cancer, triple-negative breast cancer, bladder cancer, and kidney cancer.
Officials disclosed that since this therapy has previously received "Breakthrough Therapy Designation" from the U.S. FDA, both companies plan to urgently communicate with major global regulatory agencies in the coming months and quickly submit marketing applications.
Moderna president Stephen Hoge expressed excitement in an interview, stating:
If approvals go smoothly, tens of thousands of high-risk post-surgical cancer patients could potentially use this miracle drug as early as next year (2027)!
Top investment banks predict that, for melanoma alone, the annual sales after this therapy is launched will easily exceed 3 billion dollars.
Once major cancers like lung cancer and pancreatic cancer are thoroughly conquered, a personalized AI precision medicine empire worth hundreds of billions of dollars will be fully formed.
The cost curve is also on the side of patients.
Do you remember the history of gene sequencing? The Human Genome Project burned 3 billion dollars and took 13 years; today, sequencing a whole genome costs only a few hundred dollars and results come within a day or two.
The personalized mRNA vaccine is taking the same industrialized downward path: sequencing prices are dropping, and computing power is decreasing. Once the scale is reached, marginal costs will be crushed.
Of course, there is still a gap between "thousands of people" and "millions of people," but the trend is irreversible.
References:
https://x.com/AYi_AInotes/status/2090129595794084303
https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/
https://www.modernatx.com/ir-insights-phase-3-intesmeran
https://www.reuters.com/legal/litigation/merck-moderna-say-melanoma-skin-cancer-vaccine-meets-goals-large-trial-2026-08-19/
免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。
